Quick Answer
Sensei Biotherapeutics, Inc. reported Operating Income of -$22.29 million for fiscal year 2025.
Sensei Biotherapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$22.29M | +31.7% |
| 2024 | -$32.61M | +12.0% |
| 2023 | -$37.06M | +26.1% |
| 2022 | -$50.19M | -33.9% |
| 2021 | -$37.48M | -92.7% |
| 2020 | -$19.45M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.85M | +38.0% | +6.8% |
| June 30, 2025 | -$5.21M | +33.1% | +28.4% |
| March 31, 2025 | -$7.27M | +16.7% | +7.0% |
| September 30, 2024 | -$7.82M | -1.1% | -0.5% |
| June 30, 2024 | -$7.79M | +23.5% | +10.8% |
| March 31, 2024 | -$8.73M | +20.7% | -12.8% |
| September 30, 2023 | -$7.74M | +44.5% | +24.0% |
| June 30, 2023 | -$10.18M | +5.0% | +7.5% |
- Sensei Biotherapeutics, Inc. showed an increase of +31.7% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Sensei Biotherapeutics, Inc.’s operating income has declined by 14.6% (from -$19.45 million to -$22.29 million).
- The most recent figure is from Sensei Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: